August 22, 2017 / 6:20 AM / 2 years ago

BRIEF-IP Group says Istesso has started Phase 2a trial for rheumatoid arthritis drug

Aug 22 (Reuters) - IP Group Plc

* Istesso commences phase 2a for mbs2320 in rheumatoid arthritis and expands research and development collaboration with Janssen

* Istesso has announced the successful dosing of the first patients in a Phase 2a study of its investigational drug, MBS2320, for the treatment of rheumatoid arthritis

* The progression to Phase 2a follows the successful completion of dosing in a Phase 1 study and is accompanied by an expansion of the financial terms of Istesso’s 2014 Option and Licence Agreement with Janssen Biotech, Inc. (“Janssen”).

* MBS2320 is a first-in-class metabolic reprogramming agent for the treatment of RA and is distinguished from existing treatments by its dual mode-of-action that not only reduces inflammation but may also promote bone and joint remodelling.

* Istesso is a majority-owned subsidiary of the Group and its results are consolidated into those of the Group rather than being included as a portfolio company held at fair value. Source text for Eikon: Further company coverage: (Reporting By Pamela Barbaglia)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below